A placebo-controlled, cross-over trial of aripiprazole added to obese olanzapine-treated patients with schizophrenia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 04 Feb 2013 Biomarkers information updated
- 01 Apr 2009 Results published in Journal of Clinical Psychopharmacology, April 2009.
- 17 Dec 2007 Status changed from recruiting to completed.